{"id":"NCT00784654","sponsor":"Shire","briefTitle":"Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17","officialTitle":"A Phase III, Double-blind, Placebo-controlled, Randomised Withdrawal, Multicentre, Extension, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 With Attention- Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-01-27","primaryCompletion":"2011-10-26","completion":"2011-10-26","firstPosted":"2008-11-04","resultsPosted":"2012-10-02","lastUpdate":"2021-06-09"},"enrollment":276,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["ADHD"],"interventions":[{"type":"DRUG","name":"Lisdexamfetamine dimesylate (LDX)","otherNames":["Vyvanse, SPD489"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Lisdexamfetamine dimesylate (LDX)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main aim of this study is to evaluate the long-term maintenance of efficacy of LDX after administered to children and adolescents aged 6-17 with ADHD for at least 6 months","primaryOutcome":{"measure":"Percent of Participants With Treatment Failures at End of The Randomized Withdrawal Period","timeFrame":"Baseline of the randomized withdrawal period and its relevant endpoint (Up to 6 weeks)","effectByArm":[{"arm":"Lisdexamfetamine Dimesylate (LDX)(Randomized Period)","deltaMin":15.8,"sd":null},{"arm":"Placebo (Randomized Period)","deltaMin":67.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":51,"countries":["United States","Belgium","France","Germany","Hungary","Italy","Poland","Sweden","United Kingdom"]},"refs":{"pmids":["25139785","24839883"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":276},"commonTop":["Decreased appetite","Headache","Nasopharyngitis","Weight decreased","Anorexia"]}}